Journal of Pathology and Diagnostic Microbiology

ScitechJournals

Open Access

Decifering the Code of Immunosenescence, Inflammaging& B-Cell Drift

Research Article

Ghosh S*

Department of Zoology, Dr. Harisingh Gour University, Sagar-470003, Madhya-Pradesh

***Correspondence:** Dr. Somenath Ghosh, Assistant Professor, Department of Zoology, Dr. Harisingh Gour Vishwavidyalaya, (A Central University) Sagar-470003, Madhya-Pradesh, India. E-mail: somenath9936439419@gmail.com

Received: 26 Nov, 2025; **Accepted:** 02 Dec, 2025; **Published:** 15 Dec, 2025

Copyright: © 2025 Somenath Ghosh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Executive Summary — Aging immunity is a modifiable systems failure, not an inevitability:

The age-related decline of the immune system, long considered an inevitable consequence of aging, is now understood as a modifiable, interconnected systems failure driven by two core processes: immunosenescence and inflammaging [1]. Immunosenescence is the functional deterioration of immune responses, leaving older adults vulnerable to new infections and blunting vaccine efficacy [2]. Inflammaging is a chronic, low-grade systemic inflammation that fuels nearly all major age-related diseases, from cardiovascular disorders to neurodegeneration [3]. These processes create a vicious cycle: a weakened immune system fails to clear inflammatory triggers, which in turn accelerate immune cell aging [4]. This report synthesizes the mechanisms, consequences, and emerging interventions for this critical aspect of human health.

Significant Strategic insights reveal a landscape ripe for intervention:

The Vicious "Inflamm–Immune" Loop: As we age, pro-inflammatory markers like IL-6 and TNF rise while the thymus, the T-cell factory, shrinks, drastically cutting the supply of new immune cells [1]. This creates a feedback loop where weakened defenses fail to clear inflammatory triggers, fueling chronic disease. This dual failure demands a two-pronged strategy: simultaneously reducing the burden of inflammatory senescent cells with senolytics while boosting the supply of new T-cells via thymic rejuvenation.

The Vaccine Blind-Spot: The immune system's memory becomes over-specialized with age, contracting its ability to recognize new threats. This explains why influenza vaccine efficacy drops to 40-60% in adults over 65 and why high levels of dysfunctional Age-Associated B Cells (ABCs) predict poor antibody responses to COVID-19 vaccines [4, 5]. The strategic imperative is to mandate high-dose and adjuvanted vaccines for older adults and explore pre-immunization "priming" with low-dose mTOR inhibitors to awaken the aging immune system [6, 7].

Age-Associated B Cells (ABCs) as Autoimmunity Accelerators: A dysfunctional B-cell subset, the ABCs, accumulates with age and is strongly implicated in autoimmune diseases like SLE and RA [5]. These cells secrete inflammatory signals and auto-antibodies, fanning the flames of autoimmunity. This positions ABC frequency as a critical companion diagnostic to screen patients before administering immune-stimulating therapies and suggests a new paradigm of pairing vaccines with modulators that suppress ABC expansion.

Mid-Life Immune Resilience Predicts a 15-Year Survival Gap: Groundbreaking research on "immune resilience" (IR) shows that an individual's ability to withstand inflammatory stress is a core determinant of healthy aging [8]. Adults with poor IR at age 40 face a 9.7-fold higher mortality risk, creating a 15.5-year survival gap compared to those with optimal resilience [8]. This reframes immune aging as a mid-life challenge, creating an urgent case for deploying "immune clocks" like iAge in corporate wellness

and clinical settings to identify high-risk individuals when interventions are still low-cost and effective [8].

Ultimately, the evidence points to a paradigm shift: immune aging is not a fixed trajectory but a dynamic process that can be measured, monitored, and modified. By targeting its core drivers—from senescent cells and gut dysbiosis to T-cell exhaustion and B-cell dysfunction—we can move from reactive disease treatment to proactive resilience-building, extending not just lifespan but health-span.

Anatomy of Immune Aging

Thymic Involution & Naïve Cell Crash — Single Joint T Cell Receptor Excision Cycle (sjTREC) decline and 10-fold repertoire loss:

The cornerstone of adaptive immune aging is thymic involution—the progressive shrinkage and functional collapse of the thymus gland [1]. This organ is the primary site of T-cell production, and its decline drastically curtails the output of new, "naive" T-cells, which are essential for recognizing and combating novel pathogens [1]. The result is a profound contraction of the T-cell receptor (TCR) repertoire, diminishing the diversity of threats the immune system can address [1]. This decline in thymic output is a central feature of immunosenescence, directly impairing the body's ability to mount effective primary immune responses and contributing to weakened immune surveillance [1,9].

Naïve-to-Memory Rebalancing — functional but inflexible army

As the production of naive T and B cells wanes, the immune system undergoes a fundamental shift in composition. The immune cell landscape becomes dominated by long-lived memory cells, which have accumulated over a lifetime of antigen exposure [1]. While these memory cells provide robust protection against previously encountered pathogens, their dominance comes at the cost of flexibility [2]. This imbalance, characterized by an accumulation of memory cells at the expense of naive populations, further shrinks the diversity of the immune repertoire and reduces the capacity to respond to new infections or vaccines [1,10].

Telomere Attrition & Epigenetic Drift — molecular fuse burns short

At the molecular level, immune aging is driven by cell-intrinsic processes. With each division, the protective telomere caps at the ends of immune cell chromosomes shorten. Critically short telomeres trigger a DNA damage response, leading to replicative senescence—an irreversible state of growth arrest [11]. These senescent immune cells not only lose their functional capacity but also contribute to the chronic inflammatory environment by secreting a pro-inflammatory cocktail of molecules [1]. Concurrently, widespread epigenetic alterations, including changes in DNA methylation and histone modifications, cause dysregulated gene expression, further impairing immune cell function and promoting a pro-inflammatory phenotype.

Inflammaging Engines

SASP & Senescent Cell Burden — why a few cells poison the pond

A primary engine of inflammaging is the accumulation of senescent cells in tissues throughout the body [11]. These cells, though no longer dividing, are metabolically active and secrete a complex mix of pro-inflammatory cytokines (like IL-6 and IL-8), chemokines, and proteases, known as the Senescence-Associated Secretory Phenotype (SASP) [11,12]. This persistent secretion creates a chronic, sterile, low-grade inflammatory state that is a hallmark of aging [1]. SASP not only contributes to local tissue damage but can also induce senescence in neighboring healthy cells, creating a self-perpetuating cycle that amplifies the inflammatory burden and accelerates the aging process [2].

Damage Associated Molecular Patterns (DAMPs) & Mitochondrial ROS — self-damage as chronic PAMP

Inflammaging is also fueled by the body's own internal damage signals. As cells age, mitochondrial function declines, leading to increased production of reactive oxygen species (ROS) and the release of Damage-Associated Molecular Patterns (DAMPs), such as mitochondrial DNA (mtDNA) [13]. These DAMPs are recognized by innate immune sensors like the NLRP3 inflammasome, triggering a persistent inflammatory response even in the absence of infection [13,14]. This chronic activation of innate immunity by self-derived molecules is a key contributor to the systemic inflammation seen in aging.

Gut Microbiome Dysbiosis → Endotoxemia — LPS as perpetual adjuvant

The gut microbiome is a third critical driver of inflammag-

ing [1]. With age, the gut microbiota composition shifts towards a state of dysbiosis, marked by reduced diversity and a loss of beneficial, anti-inflammatory bacteria. This imbalance can compromise the intestinal barrier, leading to increased permeability or “leaky gut”. Consequently, microbial products like lipopolysaccharide (LPS) can leak into the bloodstream, a condition called endotoxemia, which systemically activates the immune system and fuels chronic inflammation [15] This constant low-level immune stimulation from the gut contributes significantly to the overall inflammaging state.

Key takeaway: Multiple redundant triggers sustain low-grade inflammation; multihit therapy required.

Innate Immune Breakdown

Neutrophil Aging: From Killers to Collateral Damage — ↑NETs, ↓ phagocytosis, stroke risk.

The innate immune system, the body’s first line of defense, also suffers significant age-related decline [9]. Neutrophils, the most abundant innate immune cells, undergo profound changes. While their numbers may remain stable or even increase, their function deteriorates. Aged neutrophils show reduced microbicidal potential, with impaired ability to generate oxidative bursts and inhibit pathogens like *Staphylococcus aureus* [16,17]. They become more prone to releasing Neutrophil Extracellular Traps (NETs), which can contribute to tissue damage and are implicated in atherothrombotic events [17]. This dysfunction is driven by both the aged tissue microenvironment and systemic inflammaging, and it directly contributes to increased susceptibility to bacterial infections and pathologies like periodontitis [18,19].

NK & Monocyte Functional Decay — silent failures in viral surveillance

Other key innate cells also falter with age. Natural Killer (NK) cells, critical for eliminating virally infected and cancerous cells, exhibit impaired cytotoxic activity and reduced perforin release upon stimulation [16]. Monocytes and macrophages show altered functionality, including defective migration and phagocytosis, which not only impairs direct pathogen clearance but also hampers the activation of the adaptive immune system. The collective decline of these innate defenders weakens the body’s immediate response to threats and contributes to the chronic inflammatory state of inflammaging.

Innate Cell Type	Key Functional Alteration with Age	Clinical Consequences
Neutrophils	Reduced microbicidal potential (e.g., impaired TREM-1 signaling) [16] Increased release of Neutrophil Extracellular Traps (NETs) Diminished phagocytic activity and cytokine signaling	Increased susceptibility to bacterial infections (e.g., periodontitis) [19] Contribution to atherothrombotic events (heart attack, stroke)
Natural Killer (NK) Cells	Impaired cytotoxic activity and granule exocytosis Reduced frequency of key modulatory subsets (e.g., p46+) [16]	Reduced immune surveillance against viruses and tumors. Impaired resolution of inflammation.
Monocytes / Macrophages	Defective migration and phagocytosis (clearance of pathogens and senescent cells). Dysregulated cytokine production (some up, some down) [20]	Impaired antigen presentation to T cells, weakening adaptive response Contribution to chronic inflammation (inflammaging)
Dendritic Cells (DCs)	Reduced numbers of key subsets (e.g., myeloid DCs) Reduced surface area and impaired antigen presentation to T cells. [21]	Diminished activation of naive T cells - Reduced vaccine efficacy

Table 1: Functional shifts across innate cell types, metrics, and clinical fallout

Key Takeaway: The decline in innate immunity is not just a loss of function but a dangerous shift towards a dysfunctional, pro-inflammatory state that damages tissues and weakens the entire immune response.

Adaptive Immune Decline

T-Cell Exhaustion vs Senescence — PD-1 high vs CD-28null, clinical split:

The adaptive immune system’s T-cell compartment undergoes a complex remodeling process defined by two distinct states: exhaustion and senescence [1]. T-cell exhaustion is often driven by chronic antigen stimulation (e.g., from latent viruses like CMV) and is characterized by the upregulation of inhibitory receptors like PD-1, TIM-3, and TIGIT, leading to a state of reversible functional impairment [1]. In contrast, T-cell senescence is an irreversible state of cell cycle arrest, marked by the loss of the critical co-stimulatory molecule CD28 (creating CD28null T-cells) and the expression of senescence markers like KLRG1 and CD57 [1] Both states contribute to a weakened ability to fight infections and respond to vaccines, but they represent differ-

ent underlying biologies and potential therapeutic targets.

B-Cell Dysfunction & ABC Expansion — link to autoimmunity and vaccine failure:

B-cell immunity is also severely compromised with age [20]. The production of new B-cells in the bone marrow declines, and the remaining B-cells exhibit intrinsic defects that impair their ability to produce high-quality antibodies. Key processes like class-switch recombination and somatic hypermutation, which are necessary for generating diverse and high-affinity antibodies, are hampered by the reduced expression of critical factors like AID and E47 [22,23]. This results in a less diverse B-cell receptor (BCR) repertoire and lower-quality antibody responses to infections and vaccines [22].

A critical feature of B-cell aging is the accumulation of a dysfunctional subset known as Age-associated B cells (ABCs) [5]. These cells, characterized by the expression of markers like CD11c and T-bet, are potent producers of pro-inflammatory cytokines and are strongly linked to the development of autoimmune diseases [5,24]. The expansion of ABCs contributes to inflammaging and negatively correlates with vaccine responsiveness, making them a key player in the pathology of immune aging.

Biomarkers & Immune Clocks — From CRP to sc-Immu-aging:

Tracking immune aging requires moving beyond chronological age to biological age, using a suite of biomarkers and composite “immune clocks.” Simple inflammatory markers like C-reactive protein (CRP), IL-6, and TNF are well-established indicators of inflammaging and predict frailty and mortality risk [20]. Cellular markers like sjTRECs provide a direct measure of thymic output, quantifying the decline in naive T-cell production.

More advanced are composite immune clocks, which integrate multiple data points to provide a holistic measure of immune age. The iAge (Inflammatory Aging Clock) uses proteomics to identify inflammatory drivers like the chemokine CXCL9, which is linked to cardiovascular aging. The IMM-AGE clock uses longitudinal data to predict all-cause mortality. The newest frontier is single-cell clocks like sc-ImmuAging, which provide cell-type-specific aging scores and have shown potential in tracking age acceleration during COVID-19 and rejuvenation after vaccination.

Biomarker/ Clock	Type	Description & Predictive Value
CRP/Hs-CRP	Inflammatory Marker	An acute-phase protein indicating systemic inflammation. Elevated levels are a key indicator of inflammaging and are associated with increased risk of frailty and all-cause mortality.
IL-6 & TNF	Inflammatory Markers	Key pro-inflammatory cytokines and core components of SASP. Elevated levels are hallmarks of inflammaging and are associated with frailty and a wide range of age-related diseases.
sjTRECs	Cellular Marker	DNA byproducts of T-cell development in the thymus. Declining levels are a direct measure of thymic involution and a hallmark of immunosenescence, indicating a reduced capacity to respond to new antigens.
p16INK4a in T cells	Cellular Marker	A key biomarker for cellular senescence. Increased expression in T-cells indicates a higher burden of senescent immune cells and is associated with immunosenescence.
iAge (Inflammatory Aging Clock)	Composite Immune Clock	A proteomics-based clock that tracks inflammatory proteins associated with aging. It predicts multimorbidity, frailty, and cardiovascular aging, with the chemokine CXCL9 identified as a key contributor.
IMM-AGE	Composite Immune Clock	A clock developed using longitudinal data on inflammatory markers to calculate an individual's "immune age." It effectively predicts age-related health outcomes and all-cause mortality risks.
sc-ImmuAging	Composite Immune Clock	Cell-type-specific aging clocks based on single-cell transcriptomics. These clocks can decode immune aging dynamics, identify age acceleration in specific cells during infection, and reveal inter-individual variations in response to interventions.

Table 2: Key Biomarkers and Immune Clocks for Assessing Immune Aging.

Key takeaway: Composite clocks out-predict chronological age for morbidity and should guide enrollment in clinical trials for anti-aging interventions.

Clinical Consequences

Infection, Vaccine Failure & Cancer Progression — numbers that justify action:

The clinical toll of immune decline is severe and multifaceted. Older adults face a significantly higher risk of developing and dying from infections, a reality starkly highlighted by the severe outcomes of influenza and COVID-19 in this population [1]. This vulnerability is exacerbated by a dramatic reduction in vaccine responsiveness; for ex-

ample, chronic Cytomegalovirus (CMV) infection, a known driver of immunosenescence, is associated with a less effective response to the influenza vaccine [4,24]. Beyond infections, impaired immune surveillance contributes to an increased incidence of cancer and can diminish the efficacy of cancer immunotherapies in elderly patients [3]. The accumulation of dysfunctional ABCs is also linked to predicting impaired humoral immunity after COVID-19 vaccination in patients on immunotherapy.

Frailty & Multimorbidity — inflammaging as master risk factor:

Inflammaging is a central pathogenic driver for nearly all major non-communicable age-related diseases [3]. The chronic, low-grade inflammation it produces accelerates tissue damage and is a major risk factor for cardiovascular disease, neurodegenerative disorders like Alzheimer's, and metabolic syndrome [3]. This systemic inflammatory state is also strongly associated with the development of frailty, a clinical syndrome of cumulative physiological decline that increases vulnerability to stressors and leads to higher rates of hospitalization and all-cause mortality [20].

Intervention Insights:

Pharmacologic & Biologic Options:

A growing arsenal of interventions is being developed to target the core mechanisms of immune aging. These range from senolytics that clear inflammatory senescent cells to mTOR inhibitors that restore metabolic balance in immune cells.

Intervention	Category	Mechanism, Evidence & Key Risks
Dasatinib + Quercetin (D+Q)	Senolytic	Mechanism: Selectively eliminates senescent cells, reducing the SASP load that drives inflammaging. Evidence: A 2019 trial in diabetic kidney disease showed D+Q can decrease senescent cells in humans [25]. A Phase II trial (NCT04685590) is underway.
mTOR inhibitors (Everolimus, Rapamycin)	mTOR inhibitor / Rapalog	Mechanism: Inhibits the mTOR pathway to reinstate CD4+ T-cell responsiveness and reduce exhaustion markers like PD-1 [7]. Evidence: Low-dose inhibitors enhance influenza vaccine response and reduce infection incidence in the elderly with good tolerability [7].
Metformin	Geroprotector / Caloric Restriction Mimetic	Mechanism: Modulates aging pathways, corrects autophagy and mitochondrial defects in T-cells, and is a component of thymic regeneration protocols. Evidence: Partially restores immune function and enhances antiviral responses, though benefits can be modest. Showed thymic regeneration as part of a combination therapy.
NAD+ Boosters (NR, NMN)	Geroprotector / Metabolism Modulator	Mechanism: Aims to restore NAD+ levels, improving mitochondrial function, protecting against inflammation, and potentially reversing gut dysbiosis. Evidence: Animal models show NMN and NR protect against inflammation and reverse gut dysbiosis [26]. Human benefits appear modest so far.
Anti-cytokine therapies	Anti-cytokine	Mechanism: Neutralizes specific pro-inflammatory SASP cytokines (e.g., IL-1, IL-6, TNF-α) to reduce chronic inflammation. Evidence: A key strategy to mitigate immunosenescence, with active clinical trials targeting various cell types. Suppressing IL-11 is a promising avenue [14].
Probiotics	Probiotic	Mechanism: Modulates the gut microbiome to enhance immune responses and reduce inflammatory mediators, counteracting dysbiosis-driven inflammaging [27]. Evidence: Studies show certain *Lactobacilli* and *Bifidobacterium* strains can enhance influenza vaccine response and NK cell activity in the elderly [28].

Table 3: Pharmacologic & Biologic Interventions to Counteract Immune Aging

Vaccination Upgrades — High-dose, MF59, AS01, timing with mTOR-priming

To overcome age-related vaccine hypo-responsiveness, strategies have been developed to deliver a stronger stimulus to the aging immune system. High-dose vaccines, such as Fluzone High-Dose for influenza, increase the amount of antigen to elicit a more robust response [6]. Adjuvanted vaccines, like the Shingrix zoster vaccine (with AS01 adjuvant) and MF59-adjuvanted flu vaccines, use potent immunostimulants to enhance the immune reaction [6]. Adjuvants like AS03 have been shown in clinical trials to induce a multifunctional CD4+ T-cell response in the elderly, improving immunogenicity and compensating for immunosenescence [6].

Lifestyle & Dietary Levers — exercise, Mediterranean diet, CR, HIIT apoptosis of CD28null:

Lifestyle interventions are a foundational and accessible strategy for mitigating immune aging. Regular physical activity can slow immunosenescence, in part by increasing

plasma levels of IL-7 (which supports T-cell production) and decreasing pro-inflammatory IL-6 [7]. High-Intensity Interval Training (HIIT) has shown promise in selectively clearing senescent CD28null T-cells, allowing more functional cells to expand [29]. Dietary interventions, particularly those rich in fiber and polyphenols like the Mediterranean diet, enhance gut microbiota diversity, which supports a more robust immune system and reduces inflammaging [30].

Emerging Frontiers

Thymic Regeneration Protocols — GH+DHEA+Metformin, IL-7, FGF7:

A primary goal of next-generation therapies is to reverse the root cause of T-cell decline: thymic involution. Emerging strategies aim to rejuvenate the thymus and restore its ability to produce naive T-cells. One clinical trial showed that a combination of growth hormone (GH), DHEA, and metformin could reverse epigenetic aging and improve immune function. Other approaches under investigation involve using growth factors and cytokines like IL-7, IL-22, and FGF7 to promote the proliferation and survival of thymic epithelial cells, the essential support structure of the thymus [7].

HSC & Cellular Therapies — allo-HSCT, naïve-T derived CAR-T:

Another frontier involves rejuvenating the source of all immune cells: hematopoietic stem cells (HSCs). Allogeneic HSC transplantation (allo-HSCT) is already being used as a clinical modality to counteract immunosenescence in certain conditions (e.g., trial NCT06484049) [3]. Cellular therapies also hold immense promise. The adoptive transfer of T-cells that have been amplified or genetically engineered in the lab, such as CAR-T cells derived from a patient's own naive T-cells, represents a powerful approach to restoring potent, targeted immune function in an aged individual [28].

Microbiome Engineering — precision probiotics, FMT road-map:

Given the gut microbiome's profound impact on inflammaging, therapies that engineer the gut ecosystem are a major area of research. Fecal Microbiota Transplantation (FMT) is being explored to restore a more youthful and diverse microbial community, which can enhance gut immune responses and reduce systemic inflammation [30]. The development of precision probiotics, using specific bacterial strains or consortia to achieve targeted immunomodulatory effects, is another promising avenue for counteracting age-related immune decline.

Immune Resilience Framework — grading, trajectories, corporate & clinical integration:

The concept of Immune Resilience (IR) is revolutionizing the approach to healthy aging. IR is defined as the immune system's ability to maintain or rapidly restore function in the face of inflammatory stressors [14]. It is a core determinant of health span and can be measured using metrics like Immune Health Grades (IHGs), which quantify the balance between CD8+ and CD4+ T-cells, and gene expression signatures driven by the transcription factor *TCF7* [8, 31].

Studies have identified three distinct IR trajectories: IR-preservers, who maintain optimal function; IR-reconstituters, who recover after stress; and IR-degraders, who experience persistent decline [8]. The predictive power of these metrics is striking: poor IR in midlife is associated with a dramatically increased mortality risk and a significant survival gap [8]. This framework allows for the early identification of at-risk individuals, enabling proactive interventions when they are most effective.

Key takeaway: Early-life IR measurement is the cheapest longevity intervention.

Segmenting Heterogeneity

CMV, Sex, Genetics, Comorbidity Influencers — why one-size trials fail

Immune aging is not a uniform process; its rate and manifestation vary significantly between individuals [14]. This heterogeneity is driven by a combination of factors that must be accounted for in research and clinical practice. Chronic viral infections, especially with Cytomegalovirus (CMV), are a major accelerator of immunosenescence [4]. Sex also plays a role, with optimal immune resilience being more common in females, who also show a higher prevalence of autoimmunity-linked ABCs [24, 32]. Genetics and ethnicity are also key, necessitating the calibration of immune clocks for different populations. Finally, comorbidities like adiposity and other chronic inflammatory con-

ditions contribute to an individual's overall inflammaging burden and modulate their immune aging trajectory [33].

Factor	Impact on Immune Aging & Intervention Efficacy
CMV Infection	A major driver of immunosenescence, accelerating T-cell aging and exhaustion [4]. CMV+ status is linked to poorer influenza vaccine responses, potentially confounding trial results if not stratified [4].
Sex	Optimal immune resilience is more common in females [32]. Females also show a higher prevalence of ABCs, which may be linked to X-linked TLR7 dosage and contributes to the female bias in autoimmunity.
Genetics & Ethnicity	Genetic background influences the rate of immune aging. Immune clocks like sc-ImmuAging may require calibration for different ethnic populations to ensure accuracy.
Comorbidities	Conditions like increased adipose tissue or chronic inflammatory diseases contribute to the systemic inflammaging burden, accelerating immune decline and increasing risk for adverse outcomes from other stressors.

Table 4: How Key Factors Drive Heterogeneity in Immune Aging

Strategic Recommendations & Roadmap

Implement Immune Clock Screening at 40–50 years: Deploy validated immune clocks (e.g., iAge, IMM-AGE) and resilience metrics (IHGs) in clinical and corporate wellness programs to identify individuals on a high-risk trajectory for accelerated immune aging. Early identification creates a crucial window for low-cost, high-impact preventive interventions.

Layer Microbiome Repair + Exercise as Universal Baseline: Given their strong safety profile and evidence base, lifestyle interventions should be the foundation of any immune health strategy. This includes promoting diets rich in fiber and polyphenols to support a healthy gut microbiome and regular exercise (including HIIT) to reduce senescent cell load and inflammation.

Pilot Senolytics&Rapalogs in Biomarker-Defined High-Risk Elders: For individuals identified with high inflammatory burdens (e.g., high IL-6) and signs of frailty, initiate targeted clinical trials of senolytics (like D+Q) and seasonal pulses of low-dose mTOR inhibitors (rapalogs). These trials should use biomarker-guided enrollment to maximize the chance of success.

Mandate CMV Stratification in Future RCTs: The profound impact of latent CMV on immunosenescence and vaccine response means that failing to account for it can dilute or obscure the true effect of an intervention. All future clinical trials in immune aging must stratify participants by CMV serostatus or exclude CMV-positives in early-phase studies to get a clear signal.

Build Payor Models Around IR Scoring to Reimburse Prevention: Work with public and private payors to develop reimbursement models that recognize Immune Resilience (IR) scores as a valid risk-stratification tool. This would create financial incentives for preventive care, shifting the healthcare paradigm from reactive treatment of age-related diseases to proactive maintenance of immune health.

References

1. Nguyen, Thi Quynh Trang, and Kyung A. Cho. "Targeting immunosenescence and inflammaging: advancing longevity research." Experimental & Molecular Medicine (2025): 1-12.

2. Lee, Kyoo-A., Rafael R. Flores, In Hwa Jang, Ashley Saathoff, and Paul D. Robbins. "Immune senescence, immunosenescence and aging." Frontiers in Aging 3 (2022): 900028.

3. Nature Immunosenescence Review https://www.nature.com/articles/s41392-025-02371-z.

4. Falahi, Shahab, Amir Abdoli, and Azra Kenarkoohi. "Immune aging, immunosenescence, and inflammaging: implications for vaccine response in older adults." Health Science Reports 8, no. 7 (2025): e71119.

5. Ma, Shiliang, Chengwei Wang, Xinru Mao, and Yi Hao. "B cell dysfunction associated with aging and autoimmune diseases." Frontiers in immunology 10 (2019): 318.

6. Xia, Tingting, Ying Zhou, Jiayao An, Zhi Cui, Xinqin Zhong, Tianyi Cui, Bin Lv, Xin Zhao, and Xiumei Gao. "Benefit delayed immunosenescence by regulating CD4+ T cells: A promising therapeutic target for aging□related diseases." Aging Cell 23, no. 10 (2024): e14317.

7. Han, SeongJun, Peter Georgiev, Alison E. Ringel, Arlene H. Sharpe, and Marcia C. Haigis. "Age-associated remodeling of T cell immunity and metabolism." Cell Metabolism 35, no. 1 (2023): 36-55.

8. Montano, Monty. "Immune Resilience: Rewriting the Rules of Healthy Aging." Aging Cell 24, no. 6 (2025): e70089.

9. Gao, Haoyu, Eugenie Nepovimova, Vojtech Adam, Zbynek Heger, Marian Valko, Qinghua Wu, and Kamil Kuca. "Age-associated changes in innate and adaptive immunity: role of the gut microbiota." Frontiers in Immunology 15 (2024): 1421062.

10. Ciocca, Michela, Salvatore Zaffina, Ane Fernandez Salinas, Chiara Bocci, Patrizia Palomba, Maria Giulia Conti, Sara Terreri et al. “Evolution of human memory B cells from childhood to old age.” Frontiers in immunology 12 (2021): 690534.

11. Gritsenko, Anna, Jack P. Green, David Brough, and Gloria Lopez-Castejon. “Mechanisms of NLRP3 priming in inflammaging and age-related diseases.” Cytokine & growth factor reviews 55 (2020): 15-25.

12. Van Avondt, Kristof, Jan-Kolja Strecker, Claudia Tulotta, Jens Minnerup, Christian Schulz, and Oliver Soehnlein. “Neutrophils in aging and aging-related pathologies.” Immunological Reviews 314, no. 1 (2023): 357-375.

13. Chhunchha, Bhavana, Eri Kubo, Deepali Lehri, and Dhirendra P. Singh. “NLRP3 Inflammasome and Inflammatory Response in Aging Disorders: The Entanglement of Redox Modulation in Different Outcomes.” Cells 14, no. 13 (2025): 994.

14. Wrona, Marianna V., Rituparna Ghosh, Kaitlyn Coll, Connor Chun, and Matthew J. Yousefzadeh. “The 3 I’s of immunity and aging: immunosenescence, inflammaging, and immune resilience.” Frontiers in Aging 5 (2024): 1490302.

15. Haran, John P., and Beth A. McCormick. “Aging, frailty, and the microbiome—how dysbiosis influences human aging and disease.” Gastroenterology 160, no. 2 (2021): 507-523.

16. Cunha, Lucas Leite, Sandro Felix Perazzio, Jamil Azzi, Paolo Cravedi, and Leonardo Vidal Riella. “Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response.” Frontiers in immunology 11 (2020): 1748.

17. Sabbatini, Maurizio, Elisa Bona, Giorgia Novello, Mario Migliario, and Filippo Renò. “Aging hampers neutrophil extracellular traps (NETs) efficacy.” Aging clinical and experimental research 34, no. 10 (2022): 2345-2353.

18. Dou, Lei, Yang Peng, Bin Zhang, Huiyuan Yang, and Kai Zheng. “Immune remodeling during aging and the clinical significance of immunonutrition in healthy aging.” Aging and disease 15, no. 4 (2024): 1588.

19. Wang, Zi, Anish Saxena, Wenbo Yan, Silvia M. Uriarte, Rafael Siqueira, and Xin Li. “The impact of aging on neutrophil functions and the contribution to periodontitis.” International Journal of Oral Science 17, no. 1 (2025): 10.

20. Mahbub, Shegufta, Aleah L Brubaker, and Elizabeth J Kovacs. “Aging of the innate immune system: an update.” Current immunology reviews 7, no. 1 (2011): 104-115.

21. Agrawal, Anshu, and Sudhir Gupta. “Impact of aging on dendritic cell functions in humans.” Ageing research reviews 10, no. 3 (2011): 336-345.

22. de Mol, Jill, Johan Kuiper, Dimitrios Tsiantoulas, and Amanda C. Foks. “The dynamics of B cell aging in health and disease.” Frontiers in Immunology 12 (2021): 733566.

23. Cancro, Michael P., Yi Hao, Jean L. Scholz, Richard L. Riley, Daniela Frasca, Deborah K. Dunn-Walters, and Bonnie B. Blomberg. “B cells and aging: molecules and mechanisms.” Trends in immunology 30, no. 7 (2009): 313-318.

24. Mouat, Isobel C., Erin Goldberg, and Marc S. Horwitz. “Age-associated B cells in autoimmune diseases.” Cellular and Molecular Life Sciences 79, no. 8 (2022): 402.

25. Ahmed, Faraha, and Razia Khanam. “Senolytics in Brain Disorders: A Novel Pharmacological Approach to Control Cellular Senescence and Oxidative Stress.” Adaptation under Stressful Environments through Biological Adjustments and Interventions (2024): 327-342.

26. Alegre, Gabriela Fabiana Soares, and Glaucia Maria Pastore. “NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR): potential dietary contribution to health.” Current nutrition reports 12, no. 3 (2023): 445-464.

27. Decker, V., K. Qureshi, L. Roberts, N. Powell, J. R. Marchesi, B. H. Mullish, and J. L. Alexander. “The emerging role of the gut microbiota in vaccination responses.” Gut Microbes 17, no. 1 (2025): 2549585.

28. Kumar, Samayak J., Samarth Shukla, Sunil Kumar, Preeti Mishra, and Preeti Mishra Sr. “Immunosenescence and inflamm-aging: clinical interventions and the potential for reversal of aging.” Cureus 16, no. 1 (2024).

29. Rimmer, Lucy, Derek A. Mann, Avan A. Sayer, Shoba Amarnath, and Antoneta Granic. “A silver bullet for ageing medicine? Clinical relevance of T-cell checkpoint receptors in normal human ageing.” Frontiers in Immunology 15 (2024): 1360141.

30. Kanimozhi, N. V., and M. Sukumar. “Aging through the lens of the gut microbiome: Challenges and therapeutic opportunities.” Archives of Gerontology and Geriatrics Plus (2025): 100142.

31. Manoharan, Muthu Saravanan, Grace C. Lee, Nathan Harper, Justin A. Meunier, Marcos I. Restrepo, Fabio Jimenez, Sreenath Karekatt et al. “The 15-Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging.” Aging cell (2025): e70063.

32. Ahuja, Sunil K., Muthu Saravanan Manoharan, Grace C. Lee, Lyle R. McKinnon, Justin A. Meunier, Maristella Steri, Nathan Harper et al. “Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection.” Nature communications 14, no. 1 (2023): 3286.

33. Aging and the gut microbiome—growing old with our intimate friends

Citation: Somenath Ghosh. “Decifering the Code of Immunosenescence, Inflammaging& B-Cell Drift” J Pathol Diagn Microbiol (2025). 104 DOI: 10.59462/JPDM.1.1.104